Diagnostic efficacy of cystatin C for vascular Parkinsonism

doi:10.3969/j.issn.1004-583X.2021.11.005

Abstract

Abstract:

Objective To analyze the diagnostic efficacy of cystatin C(Cys C) for vascular Parkinsonism(VP). Methods Fifty-six inpatients with VP in Central Hospital of Jinzhou from December 2019 to May 2021 were included in VP group. In the same period, 51 inpatients with Parkinson's disease(PD) in PD group, and 50 healthy physical examiners at outpatient in healthy control group. The general clinical data and serum biochemical indexes were collected for analysis. The correlation between serum Cys C and other serum indexes in VP were compared and judged in auxiliary diagnostics. Results Compared with PD group, triglyceride(TG), low-density lipoprotein cholesterol(LDL-C) and homocysteine(Hcy) in VP group showed significantly increase, and the prevalence rates of cerebral infarction(CI), hypertension and hyperlipidemia were higher (P<0.05, P<0.01). Compared with control group, age, male, serum Cys C, TG, LDL-C and Hcy in VP group were significantly increased, and the prevalence rates of CI, hypertension, diabetes, hyperlipidemia and coronary heart disease(CHD) were higher,too(P<0.05, P<0.01). Logistic regression analysis showed that risks for VP were age, the history of CI, Cys C, TG, LDL-C and Hcy (P<0.05, P<0.01). ROC curve analysis showed that AUC of Cys C, TG, LDL-C, Hcy and Cys C+TG+LDL-C+Hcy in auxiliary diagnosis for VP were 0.764(95%CI:0.671-0.857, P=0.000), 0.801(95%CI: 0.718-0.884, P=0.000), 0.751(95%CI: 0.657-0.844, P=0.000), 0.723(95%CI: 0.627-0.818, P=0.000) and 0.920(95%CI: 0.870-0.969, P=0.000).Conclusion Serum Cys C combined with TG, LDL-C and Hcy may have potential auxiliary diagnosis and differential diagnostic value in VP.

Key words: vascular Parkinson's syndrome, cystatin C, diagnostic efficiency

CLC Number:

Shen Huinan, Guo Chang, Sun Yimeng, Wang Dongyu. Diagnostic efficacy of cystatin C for vascular Parkinsonism[J]. Clinical Focus, 2021, 36(11): 986-990.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.11.005

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I11/986

Figures/Tables 3

References 35

[1]	Fleury V, Brindel P, Nicastro N, et al. Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland[J]. Parkinsonism Relat Disord, 2018, 54:30-39. doi: 10.1016/j.parkreldis.2018.03.030 URL
[2]	辛虹昕. 老年血管性帕金森综合征的临床特点分析[J]. 世界最新医学信息文摘(连续型电子期刊), 2021, 21(3):103-104.
[3]	张国平, 贺茂林, 王莉莉, 等. 血管性帕金森综合征临床特点分析[J]. 中国全科医学, 2012, 15(24):2805-2806.
[4]	Vale TC, Barbosa MT, Resende EPF, et al. Parkinsonism in a population-based study of individuals aged 75+ years: The Pietà study[J]. Parkinsonism Relat Disord, 2018, 56:76-81. doi: 10.1016/j.parkreldis.2018.06.030 URL
[5]	Zou J, Chen Z, Wei X, et al. Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units[J]. Cell Death Dis, 2017, 8(6):e2854.
[6]	杨光, 徐陈陈, 王佳炜, 等. 帕金森病患者血清同型半胱氨酸及血脂水平与脑白质病变的相关性研究[J]. 中华全科医学, 2021, 19(9):1451-1454+1503.
[7]	Vale TC, Caramelli P, Cardoso F. Clinicoradiological comparison between vascular parkinsonism and Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 2015, 86(5):547-553. doi: 10.1136/jnnp-2014-307867 pmid: 25006209
[8]	Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2015, 30(12):1591-1601. doi: 10.1002/mds.26424 URL
[9]	杨海婷, 尤和阳, 杨晨, 等. 帕金森病与血管性帕金森综合征患者疼痛程度及其与运动障碍及生活质量的关系研究[J]. 中国全科医学, 2020, 23(23):2901-2907. doi: 10.12114/j.issn.1007-9572.2020.00.187
[10]	王丹, 于海华, 冯凯. 老年血管性帕金森综合征的临床特点分析[J]. 中华老年心脑血管病杂志, 2019, 21(10):1067-1069.
[11]	谈世东, 强朝晖. 血管性帕金森综合征和帕金森病颈动脉彩色超声及经颅多普勒检查临床分析[J]. 中国实用神经疾病杂志, 2020, 23(5):411-415.
[12]	罗倩, 彭思佳, 王笑瑗, 等. 血管性帕金森综合征的临床特征及神经影像学研究进展[J]. 中国卒中杂志, 2021, 16(9):967-970.
[13]	张绿明, 万志荣, 韩旭, 等. 血管性帕金森综合征与帕金森病影像学脑白质病变及“燕尾征”改变的差异[J]. 临床神经病学杂志, 2020, 33(5):371-374.
[14]	Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study[J]. Stroke, 1997, 28(5):965-969. pmid: 9158634
[15]	Wegner F, Strecker K, Schwarz J, et al. Vascular parkinsonism in a CADASIL case with an intact nigrostriatal dopaminergic system[J]. J Neurol, 2007, 254(12):1743-1745. doi: 10.1007/s00415-007-0529-4 pmid: 18004646
[16]	Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review[J]. Mov Disord, 2010, 25(2):149-156. doi: 10.1002/mds.22937 URL
[17]	王丽娟, 聂坤, 张玉虎. 血管性帕金森综合征的诊治[J]. 中华神经科杂志, 2021, 54(8):833-837.
[18]	焦玲, 楚兰. 血管性帕金森综合征的临床与头部MRI研究[J]. 中风与神经疾病杂志, 2010, 27(4):355-356.
[19]	冯之英, 李秀华, 朱梅佳, 等. 血管性帕金森综合征与帕金森病的临床与影像学特点[J]. 山东医药, 2014(37):1-3, 7.
[20]	Rothenbacher D, Rehm M, Iacoviello L, et al. Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project[J]. BMC Med, 2020, 18(1):300. doi: 10.1186/s12916-020-01776-7 pmid: 33161898
[21]	肖改娥, 马莹, 李婷, 等. 血清Cys-C、β2-MG、Fetuin-A与老年糖尿病肾病的相关性研究[J]. 临床血液学杂志, 2021, 34(10):693-696.
[22]	郭建伟, 徐思琪, 宁瑶, 等. 脑卒中高危人群脉压和胱抑素C与颈动脉斑块的相关性研究[J]. 中国慢性病预防与控制, 2021, 29(9):703-706.
[23]	郭姗姗, 陈红霞, 武一平, 等. 血管性帕金森综合征的研究进展[J]. 中国卒中杂志, 2018, 13(9):990-994.
[24]	Hirao K, Yamashita F, Tsugawa A, et al. Association of serum cystatin C with white matter abnormalities in patients with amnestic mild cognitive impairment[J]. Geriatr Gerontol Int, 2019, 19(10):1036-1040. doi: 10.1111/ggi.v19.10 URL
[25]	Deng A, Irizarry MC, Nitsch RM, et al. Elevation of cystatin C in susceptible neurons in Alzheimer's disease[J]. Am J Pathol, 2001, 159(3):1061-1068. pmid: 11549598
[26]	Nakane S, Fujita K, Azuma S, et al. CSF cystatin C and diffusion tensor imaging parameters as biomarkers of upper motor neuron degeneration in amyotrophic lateral sclerosis[J]. Clin Neurol Neurosurg, 2018, 172:162-168. doi: 10.1016/j.clineuro.2018.07.008 URL
[27]	Kaur G, Mohan P, Pawlik M, et al. Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy[J]. Am J Pathol, 2010, 177(5):2256-2267. doi: 10.2353/ajpath.2010.100461 URL
[28]	Nair P, Misra S, Nath M, et al. Cystatin C and risk of mild cognitive impairment: A systematic review and meta-analysis[J]. Dement Geriatr Cogn Disord, 2020, 49(5):471-482.
[29]	Wang Y, Li W, Yang J, et al. Association between cystatin C and the risk of ischemic stroke: a system-atic review and meta-analysis[J]. J Mole Neurosci, 2019, 69:444-449.
[30]	Zou J, Chen Z, Wei X, et al. Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units[J]. Cell Death Dis, 2017, 8(6):e2854.
[31]	杨光, 徐陈陈, 王佳炜, 等. 帕金森病患者血清同型半胱氨酸及血脂水平与脑白质病变的相关性研究[J]. 中华全科医学, 2021, 19(9):1451-1454+1503.
[32]	刘春苗, 程启惠. 胱抑素C、同型半胱氨酸与帕金森病病情进展的相关性研究[J]. 重庆医学, 2016, 45(26):3700-3702.
[33]	Licking N, Murchison C, Cholerton B, et al. Homocysteine and cognitive function in Parkinson's disease[J]. Parkinsonism Relat Disord, 2017, 44:1-5. doi: 10.1016/j.parkreldis.2017.08.005 URL
[34]	李尤, 高玉元, 聂坤, 等. 血清生化指标对血管性帕金森综合征患者的辅助诊断价值[J]. 中华老年心脑血管病杂志, 2020, 22(5):493-496.
[35]	冯广龙, 姜慧杰. ROC曲线分析在医学影像学诊断中的价值[J]. 中华医学杂志, 2015, 95(3):231-233.

项目	VP组(n=56)	PD组(n=51)	健康对照组(n=50)	χ²值/F值	P值
年龄(岁)	71.29±4.97	64.25±4.31	63.80±4.19	46.476	<0.01
男性[例(%)]	42(75.00)	29(56.86)^*	28(56.00)	5.338	<0.05
脑梗死病史[例(%)]	41(73.21)	8(15.69)	0(0.00)	80.769	<0.01
高血压病史[例(%)]	18(32.14)	6(11.76)	0(0.00)^*	23.633	<0.05
糖尿病病史[例(%)]	12(21.43)	6(11.76)	0(0.00)^*	13.785	<0.05
高脂血症史[例(%)]	35(62.50)	16(31.37)^*	0(0.00)^*△	56.255	<0.01
冠心病病史[例(%)]	7(12.50)	3(5.88)	0(0.00)^△	7.070	<0.05
CysC(mmol/L)	1.54±0.75	0.99±0.39^*	0.71±0.18^*△	39.597	<0.05
TC (mmol/L)	4.76±1.02	4.42±1.14	4.36±1.12	2.144	>0.05
TG(mmol/L)	1.93±0.61	1.23±0.53	1.24±0.52	28.527	<0.01
HDL-C(mmol/L)	1.28±0.26	1.30±0.32	1.30±0.33	0.059	>0.05
LDL-C(mmol/L)	3.01±0.85	2.27±0.71	2.26±0.70	17.301	<0.01
Hcy(mmol/L)	17.90±6.01	13.41±4.10	12.64±3.21	20.751	<0.01
FBG(mmol/L)	5.55±0.76	5.35±0.63	5.32±0.48	1.429	>0.05
UA(μmmol/L)	311.59±70.61	295.22±62.76	295.24±63.39	1.112	>0.05

项目	VP组(n=56)	PD组(n=51)	健康对照组(n=50)	χ²值/F值	P值
年龄(岁)	71.29±4.97	64.25±4.31	63.80±4.19	46.476	<0.01
男性[例(%)]	42(75.00)	29(56.86)^*	28(56.00)	5.338	<0.05
脑梗死病史[例(%)]	41(73.21)	8(15.69)	0(0.00)	80.769	<0.01
高血压病史[例(%)]	18(32.14)	6(11.76)	0(0.00)^*	23.633	<0.05
糖尿病病史[例(%)]	12(21.43)	6(11.76)	0(0.00)^*	13.785	<0.05
高脂血症史[例(%)]	35(62.50)	16(31.37)^*	0(0.00)^*△	56.255	<0.01
冠心病病史[例(%)]	7(12.50)	3(5.88)	0(0.00)^△	7.070	<0.05
CysC(mmol/L)	1.54±0.75	0.99±0.39^*	0.71±0.18^*△	39.597	<0.05
TC (mmol/L)	4.76±1.02	4.42±1.14	4.36±1.12	2.144	>0.05
TG(mmol/L)	1.93±0.61	1.23±0.53	1.24±0.52	28.527	<0.01
HDL-C(mmol/L)	1.28±0.26	1.30±0.32	1.30±0.33	0.059	>0.05
LDL-C(mmol/L)	3.01±0.85	2.27±0.71	2.26±0.70	17.301	<0.01
Hcy(mmol/L)	17.90±6.01	13.41±4.10	12.64±3.21	20.751	<0.01
FBG(mmol/L)	5.55±0.76	5.35±0.63	5.32±0.48	1.429	>0.05
UA(μmmol/L)	311.59±70.61	295.22±62.76	295.24±63.39	1.112	>0.05

影响因素	回归系数	标准误	Wald χ²值	OR值	P值	95%CI
影响因素	回归系数	标准误	Wald χ²值	OR值	P值	下限	上限
年龄	0.685	0.217	9.976	1.984	0.002	1.297	3.034
脑梗死病史	3.002	1.269	5.600	1.050	0.018	0.004	0.597
Cys C	3.184	1.135	5.869	1.154	0.015	1.837	3.622
TG	3.807	1.458	6.819	1.107	0.009	2.585	4.092
LDL-C	2.754	1.036	7.060	1.699	0.008	2.059	2.678
Hcy	0.431	0.192	5.023	1.538	0.025	1.056	2.241

影响因素	回归系数	标准误	Wald χ²值	OR值	P值	95%CI
影响因素	回归系数	标准误	Wald χ²值	OR值	P值	下限	上限
年龄	0.685	0.217	9.976	1.984	0.002	1.297	3.034
脑梗死病史	3.002	1.269	5.600	1.050	0.018	0.004	0.597
Cys C	3.184	1.135	5.869	1.154	0.015	1.837	3.622
TG	3.807	1.458	6.819	1.107	0.009	2.585	4.092
LDL-C	2.754	1.036	7.060	1.699	0.008	2.059	2.678
Hcy	0.431	0.192	5.023	1.538	0.025	1.056	2.241

项目	AUC	敏感性	特异性	约登指数	临界值	P值	95%CI
项目	AUC	敏感性	特异性	约登指数	临界值	P值	下限	上限
年龄	0.845	0.679	0.961	0.64	68.5	0.000	0.772	0.918
Cys C+TG+LDL-C+Hcy	0.920	0.964	0.706	0.67	-	0.000	0.870	0.969
TG	0.801	0.607	0.902	0.509	1.82	0.000	0.718	0.884
LDL-C	0.751	0.732	0.765	0.497	2.565	0.000	0.657	0.844
Hcy	0.723	0.75	0.627	0.377	14.945	0.000	0.627	0.818
Cys C	0.764	0.696	0.804	0.5	1.29	0.000	0.671	0.857